CaSRevolution

CaSRevolution

Milan, Italy· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

CaSRevolution is a private, preclinical-stage biotech pioneering a novel CRISPR-based gene therapy platform targeting neurodegenerative diseases. Founded in Milan in 2019, the company is developing potentially curative approaches that aim to modify disease progression, a significant unmet need in neurology. While still in early research and development, its focus on cutting-edge genetic tools positions it in a high-potential but competitive segment of the biopharma industry. The company appears to be in a foundational, pre-revenue stage, building its technology and pipeline.

Neurodegenerative Diseases

Technology Platform

CRISPR-based gene editing platform combined with gene therapy delivery systems, aimed at creating disease-modifying treatments for neurological disorders.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The global neurodegenerative disease market represents a massive, underserved opportunity for any disease-modifying therapy.
Advances in vector design for brain delivery and the continued evolution of more precise CRISPR tools (e.g., base editing, prime editing) could accelerate and de-risk the platform's application.

Risk Factors

Extreme technical risk associated with delivering gene editing components to the brain safely and effectively.
High competitive and financial risk as a small, early-stage player in a capital-intensive field dominated by large, well-funded entities.

Competitive Landscape

Highly competitive. CaSRevolution competes with large-cap gene editing leaders (e.g., CRISPR Therapeutics, Intellia, Editas) and numerous neurology-focused biotechs developing gene therapies, antisense oligonucleotides, and other modalities. Differentiation will require demonstrating superior delivery, editing efficiency, or safety in the CNS.